drugset / Trial / NCT04344678

The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

NCT04344678

RandomizedParallel-groupDouble-blindTreatment

Summary

Antidepressant-like effects of sildenafil to its ability to modulate transduction pathways responsible for neuroplasticity. Treatment with sildenafil was shown to be PKG-dependent and lead to increased expression of cGMP, pCREB, BDNF and VGF in the hippocampus and prefrontal cortex (PFC), brain areas relevant to mood disorders pathophysiology. Sildenafil produces antidepressant-like effects by inhibiting oxidative stress in the hippocampus and by decreasing the levels of IL-1β in the hippocampus and striatum.

Timeline

Start
2020-01-01
Primary completion
2024-10-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 50 mg
Background Escitalopram Small molecule 20 mg